Skip to main content
. 2022 Dec 30;101(52):e32439. doi: 10.1097/MD.0000000000032439

Table 1.

Clinical characteristics.

Characteristic (N = 245) Mean ± SD, number (%)
Age 61.7 ± 12.1
Male sex (%) 218 (89.0)
Height (cm) 168.2 ± 8.0
BMI (kg/m2) 25.2 ± 4.0
Underlying disease
Hypertension (%) 163 (66.5)
Dyslipidemia (%) 183 (74.7)
Diabetes mellitus (%) 81 (33.1)
Atrial fibrillation (%) 9 (3.7)
Prior MI (%) 26 (10.6)
Prior PCI (%) 33 (13.5)
Prior CABG (%) 4 (1.6)
History of heart failure (%) 6 (2.4)
History of stroke (%) 13 (5.3)
Smoking history
Current smoker (%) 82 (33.4)
Past smoker (%) 89 (36.3)
Never smoked (%) 74 (30.2)
Medication
Calcium channel blockers (%) 76 (31.0)
Beta blockers (%) 39 (16.0)
ACE inhibitors (%) 13 (5.3)
ARBs (%) 57 (23.3)
Nitrates (%) 14 (5.7)
Nicorandil (%) 10 (4.0)
Statins (%) 58 (23.7)
Oral antidiabetic agents (%) 46 (18.8)
Insulin (%) 7 (2.9)
Aspirin (%) 53 (21.6)
Clopidogrel (%) 16 (6.5)
Prasugrel (%) 6 (2.4)
Cilostazol (%) 6 (2.4)
Ticlopidine (%) 1 (0.4)
SAPT (%) 40 (16.3)
DAPT (%) 19 (7.8)
Warfarin (%) 1 (0.4)
Rivaroxaban (%) 2 (0.8)
Apixaban (%) 1 (0.4)
Edoxaban (%) 1 (0.4)
Predonine (%) 5 (2.0)
Diagnosis
STEMI (%) 149 (60.8)
NSTEMI (%) 48 (19.6)
UA (%) 48 (19.6)
Emergent PCI (%) 236 (96.3)
Received PCI (%) 243 (99.1)
Length of hospital stay (d) 9.8 ± 6.4
Length of hospital stay for STEMI (d) 12.4 ± 6.1
Length of hospital stay for NSTEMI (d) 7.4 ± 4.8
Length of hospital stay for UA (d) 4.0 ± 3.0

ACE = angiotensin converting enzyme, ARBs = angiotensin II type I receptor blockers, BMI = body mass index, CABG = coronary artery bypass grafting, DAPT = dual antiplatelet therapy, MI = myocardial infarction, NSTEMI = non-ST elevation myocardial infarction, PCI = percutaneous coronary intervention, SAPT = single antiplatelet therapy, STEMI = ST elevation myocardial infarction, UA = unstable angina.